Viewing Study NCT03881735

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:32 PM
Ignite Modification Date: 2026-01-04 @ 8:22 AM
Study NCT ID: NCT03881735
Status: WITHDRAWN
Last Update Posted: 2021-03-10
First Post: 2019-03-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Sponsor: Roswell Park Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Blasts Under 5 Percent of Peripheral Blood White Cells View
None Bone Marrow Blasts Decreased by 50 Percent or More Compared … View
None IDH2 Gene Mutation View
None Recurrent Acute Myeloid Leukemia View
None Refractory Acute Myeloid Leukemia View
Keywords: